Close

Anti-CD20 (Obinutuzumab)-CD147 CAR-MA (CARMA-W0085)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CD20 chimeric antigen receptor (CAR) is constructed for the engineering of macrophage cells to target human CD20 and induce target cell phagocytosis. The macrophage cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD20 antibody (Obinutuzumab) linked to CD147 signaling domains. The vector product was designed for the treatment of Lymphoma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD20
  • Cell Type
  • Macrophage
  • Targeting Diseases
  • Lymphoma
  • Vector Name
  • pCDCAR1
  • Vector length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Size
  • 10 µg
  • Storage
  • Store at -20°C for long term.

CAR Components

  • Promoter
  • EF1a
  • scFv
  • Obinutuzumab
  • Hinge
  • IgG1
  • TM
  • CD147
  • ICD
  • CD147
  • Marker
  • GFP or N/A
  • Receptor Construction
  • scFv-hinge(IgG1)-TM(CD147)-ICD(CD147)
  • Discription of Signaling Cassetes
  • To breakdown the "physical barrier" of the tumour matrix, CD147 is used as the signaling domain. It's a membrane molecule that is essential for ECM remodelling via the expression of MMPs.

Target

  • Target
  • CD20
  • Target Species
  • Human
  • Clone
  • Obinutuzumab
  • Host
  • Human
  • Gene Name
  • Membrane spanning 4-domains A1
  • Introduction
  • This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein.
  • Alternative Names
  • B1; S7; Bp35; CD20; FMC7; CVID5; LEU-16; MS4A1; Membrane spanning 4-domains A1

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD20 (Obinutuzumab) ICD(CD147) CAR-MA Plasmid, pCDCAR1 (CARMA-W0085). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.